


The principle

Immunoprecipitation (IP) is a method to isolate a specific antigen from a mixture, using the antigen-antibody interaction. Antigens isolated by IP are analyzed by SDS-PAGE or Western blotting.



In IP, an antibody is added first to a mixture containing an antigen, and incubated to allow antigen-antibody complexes to form. Subsequently, the antigen-antibody complexes are incubated with an immobilized antibody against the primary antibody (secondary antibody) or with protein A/G-coated beads to allow them to absorb the complexes. The beads are then thoroughly washed, and the antigen is eluted from the beads by an acidic solution or SDS.

If a suitable antibody is not available, the target molecule is fused to a His tag or other tags by recombinant DNA techniques, and immunoprecipitated using an antibody to the tag (pull-down assay).


The use of an antibody with high binding specificity and affinity for the antigen is critical for successful IP. Antibodies raised against synthetic peptides and recombinant proteins often work well in Western blotting but may not bind the antigens in their native conformation in solution. When using commercial antibodies, select the ones that are suitable for IP according to product information. Also recognize the properties of both the antibody and antigen in the literature and product information.

Tips for efficient IP

The diagram on the right illustrates the structures of antigen-antibody complexes formed with a monoclonal versus polyclonal antibody as the primary antibody. When using a monoclonal antibody as the primary antibody, adjust the concentration so that:

[Secondary antibody] > [Primary antibody] > [Antigen].

An excess of primary antibody, relative to the secondary antibody, may compete with antigen-antibody complexes for the secondary antibody, resulting in a lower yield of recovery. When using a polyclonal antibody, an excess of primary antibody, relative to the antigen, will prevent the formation of oligomeric complexes. Therefore, these concentrations should be optimized by testing different ratios.



Comparison of primary antibodies for IP

	Monoclonal Antibody	Polyclonal Antibody
Background	Background is low with an appropriate antibody because the antibody recognizes a single antigen.	Background may be high if some of the antibody molecules have a low specificity and bind to proteins other than the target protein.
Binding affinity	High-affinity monoclonal antibody (dissociation constant $K_d < 10^{-8}$ M) should be used because low affinity antibody may not form an antigen-antibody complex in solution.	Even if the affinity of individual antibody molecules is low, oligomeric antigen-antibody complexes are formed easily due to the multivalent binding.
Stability of antigen-antibody complexes	If the binding affinity of an antibody is low, simultaneously using several high-specificity monoclonal antibodies will allow multivalent binding, resulting in stable antigen-antibody.	Stable oligomeric complexes are formed because reaction between a polyclonal antibody and an antigen is multivalent

Beads for immobilization

complexes

Agarose beads and magnetic beads are commonly used. Agarose beads have a porous, mesh-like structure, and antibodies can diffuse and bind to the internal matrix of the beads, which provides high binding capacity. Magnetic beads are simple spheres, providing ease of handling and short processing time. With appropriate coating, background can be reduced. However, binding capacity may not be high enough for some applications, and the cost is higher than the alternative using agarose beads.

Magnetic agarose beads provide ease of handling (when used with a magnet) and a high binding capacity.

Description of Each Conjugate

Smart-IP tag-antibodies conjugated with magnetic beads or magnetic agarose

Detergents Appropriate concentrations of salt and non-ionic detergent are commonly used in IP to reduce non-specific binding (protein-protein

and protein-bead interactions). Pilot experiments should be performed with detergents, which may reduce the affinity of the antibody, especially when using a monoclonal antibody.

The target protein and antibody

Protease inhibitors

The target protein and antibody are subject to degradation by protein-degrading enzymes (proteases) in samples such as cell lysates and tissue extracts. To prevent proteolytic degradation, protease inhibitors are included. When the type of proteases in samples are known or predicted, specific inhibitors are used. When proteases are unknown, a combination of multiple small molecule inhibitors, such as PMSF and EDTA, are used.

Elution condition In most applications, proteins are eluted in SDS sample buffer containing a reducing agent, such as 2-mercaptoethanol (2-ME). In


addition to the target protein, the antibodies used for IP are co-eluted, which should be considered when performing Western blotting or mass analysis.


IP (with agarose beads)

Procedure

An example performed at MBL

Step-by-step procedure





<When extracting the target protein while preserving its activity and native conformation (pull-down assay)>
Elute the target protein in neutral pH using an elution peptide and avoid harsh conditions, such as acidic

* For the most up to date product information and protocols, please visit mblintl.com | For Research Use Only, Not for use in diagnostic procedures.

*The antibodies are co-eluted, which should be

taken into account when analyzing the data.

and alkaline solutions.